U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H21F3N2O4S
Molecular Weight 478.484
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GW-590735

SMILES

CC1=C(SC(=N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NCC3=CC=C(OC(C)(C)C(O)=O)C=C3

InChI

InChIKey=ILUPZUOBHCUBKB-UHFFFAOYSA-N
InChI=1S/C23H21F3N2O4S/c1-13-18(33-20(28-13)15-6-8-16(9-7-15)23(24,25)26)19(29)27-12-14-4-10-17(11-5-14)32-22(2,3)21(30)31/h4-11H,12H2,1-3H3,(H,27,29)(H,30,31)

HIDE SMILES / InChI

Molecular Formula C23H21F3N2O4S
Molecular Weight 478.484
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPARα results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1461 ng/mL
3 mg/kg single, oral
dose: 3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
GW-590735 plasma
Rattus norvegicus
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
2.7 mg/kg single, intravenous
dose: 2.7 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GW-590735 plasma
Rattus norvegicus
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
2008 Oct
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
2010 Apr
Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
2010 Jun
Patents

Sample Use Guides

eight weeks treatment with 1µg to 20µg daily doses of GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and normal LDLc
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: GW590735 shows EC50 = 4 nM on PPARalpha and at least 500-fold selectivity versus PPARdelta and PPARgamma.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:17 GMT 2023
Edited
by admin
on Fri Dec 15 15:43:17 GMT 2023
Record UNII
QKY617BBX5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GW-590735
Common Name English
PROPANOIC ACID, 2-METHYL-2-(4-((((4-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)-5-THIAZOLYL)CARBONYL)AMINO)METHYL)PHENOXY)-
Common Name English
Code System Code Type Description
PUBCHEM
9956726
Created by admin on Fri Dec 15 15:43:17 GMT 2023 , Edited by admin on Fri Dec 15 15:43:17 GMT 2023
PRIMARY
FDA UNII
QKY617BBX5
Created by admin on Fri Dec 15 15:43:17 GMT 2023 , Edited by admin on Fri Dec 15 15:43:17 GMT 2023
PRIMARY
CAS
343321-96-0
Created by admin on Fri Dec 15 15:43:17 GMT 2023 , Edited by admin on Fri Dec 15 15:43:17 GMT 2023
PRIMARY
DRUG BANK
DB07215
Created by admin on Fri Dec 15 15:43:17 GMT 2023 , Edited by admin on Fri Dec 15 15:43:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID90977813
Created by admin on Fri Dec 15 15:43:17 GMT 2023 , Edited by admin on Fri Dec 15 15:43:17 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> ACTIVATOR
EC50
TARGET -> ACTIVATOR
EC50
Related Record Type Details
ACTIVE MOIETY